KRAS and neoplasm: These findings help contextualize the activity of KRAS inhibitors in advanced PDAC, where they preferentially eliminate basal/mesenchymal-like populations and remodel the tumor microenvironment, in some instances enhancing responsiveness to immunotherapy112–115.